319 related articles for article (PubMed ID: 11531934)
1. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study.
Chen M; Chow SN
Clin Endocrinol (Oxf); 2001 Aug; 55(2):253-8. PubMed ID: 11531934
[TBL] [Abstract][Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
[TBL] [Abstract][Full Text] [Related]
4. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.
Wimalawansa SJ
Am J Med; 1995 Jul; 99(1):36-42. PubMed ID: 7598140
[TBL] [Abstract][Full Text] [Related]
6. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
8. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study.
Komulainen M; Tuppurainen MT; Kröger H; Heikkinen AM; Puntila E; Alhava E; Honkanen R; Saarikoski S
Osteoporos Int; 1997; 7(2):126-32. PubMed ID: 9166392
[TBL] [Abstract][Full Text] [Related]
10. Effects on bone mass after eight years of hormonal replacement therapy.
Eiken P; Nielsen SP; Kolthoff N
Br J Obstet Gynaecol; 1997 Jun; 104(6):702-7. PubMed ID: 9197874
[TBL] [Abstract][Full Text] [Related]
11. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
12. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
[TBL] [Abstract][Full Text] [Related]
13. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
14. Prevention of postmenopausal bone loss with exchange for short-term HRT for 1alpha-hydroxycholecalciferol.
Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
Maturitas; 2003 Jun; 45(2):119-27. PubMed ID: 12787970
[TBL] [Abstract][Full Text] [Related]
15. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
16. Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?
Heikkinen AM; Kröger H; Niskanen L; Komulainen MH; Ryynänen M; Parviainen MT; Tuppurainen MT; Honkanen R; Saarikoski S
Maturitas; 2000 Jan; 34(1):33-41. PubMed ID: 10687880
[TBL] [Abstract][Full Text] [Related]
17. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
[TBL] [Abstract][Full Text] [Related]
18. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
19. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
20. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis.
Ormarsdóttir S; Mallmin H; Naessén T; Petrén-Mallmin M; Broomé U; Hultcrantz R; Lööf L
J Intern Med; 2004 Jul; 256(1):63-9. PubMed ID: 15189367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
